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ABSTRACT: Recent studies suggest that cardiac fibroblast-specific p38a MAPK contributes to the development of
cardiac hypertrophy, but the underlying mechanism is unknown. Our study used a novel fibroblast-specific,
tamoxifen-inducible p38a knockout (KO) mouse line to characterize the role of fibroblast p38a in modulating
cardiac hypertrophy, and we elucidated the mechanism. Myocardial injury was induced in tamoxifen-treated Cre-
positivep38aKOmice or control littermatesvia chronic infusionof theb-adrenergic receptor agonist isoproterenol.
Cardiac function was assessed by pressure–volume conductance catheter analysis and was evaluated for cardiac
hypertrophy at tissue, cellular, andmolecular levels. Isoproterenol infusion in control mice promoted overt cardiac
hypertrophy and dysfunction (reduced ejection fraction, increased end systolic volume, increased cardiac weight
index, increased cardiomyocyte area, increased fibrosis, and up-regulation ofmyocyte fetal genes andhypertrophy-
associatedmicroRNAs). Fibroblast-specific p38a KOmice exhibitedmarked protection against myocardial injury,
with isoproterenol-inducedalterations in cardiac function,histology, andmolecularmarkers all beingattenuated. In
vitro mechanistic studies determined that cardiac fibroblasts responded to damaged myocardium by secreting
several paracrine factors known to induce cardiomyocyte hypertrophy, including IL-6, whose secretion was de-
pendent upon p38a activity. In conclusion, cardiac fibroblast p38a contributes to cardiomyocyte hypertrophy and
cardiac dysfunction, potentially via a mechanism involving paracrine fibroblast-to-myocyte IL-6 signaling.—
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The p38 family of stress-activated MAPKs has an impor-
tant role in cardiac signaling and is activated in both acute
and chronic cardiac pathologies including myocardial
infarction, left ventricular (LV) remodeling, contractile
dysfunction, arrhythmia, and heart failure (1–4). A host of
preclinical studies have demonstrated that p38 MAPK
inhibition can reduce the adverse consequences of cardiac
injury or stress (1–4).
There are 4 known p38 subtypes (a, b, g, and d); p38a
and p38b share sequence homology and, unlike p38g and
p38d, are inhibited by the pyridinyl imidazole class of p38
inhibitors (e.g., SB203580). The expression and function
of individual p38 subtypes varies in a cell- and tissue-
dependent manner; p38a is the most highly expressed
subtype in the heart, with lower levels of p38g and p38d,
and little or no expression of p38b (5, 6). p38a knockout
(KO)mice arenotviablebecauseof anessential role for this
subtype in placental development (7).
Most studies on p38 subtypes in the heart have focused
on the a and b subtypes (1–4). In vitro experiments in-
volving ectopic overexpression of p38a/b suggested a role
for the b rather than the a subtype in stimulating car-
diomyocyte hypertrophy (8, 9). However, the relatively
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low endogenous expression of p38b in heart tissue, com-
pared with p38a and other p38 subtypes (5, 6), may ques-
tion the physiologic importance of those findings. Several
studies in a variety of species and cardiac-injury models
have reported that combined pharmacologic inhibition of
p38a and b is effective at reducing cardiac hypertrophy
(10). Similar cardioprotective effects were obtained with a
p38a-selective inhibitor in an isoproterenol (ISO)-induced
model of cardiac hypertrophy and dysfunction in rats (11),
which suggested it was p38a, rather than p38b, which
is important in mediating cardiac hypertrophy in vivo.
However, when p38a has been selectively inhibited in
cardiomyocytes in vivo (with either cardiomyocyte-specific
KO or dominant-negative approaches), there was no ap-
parent benefit on cardiac or cardiomyocyte hypertrophy,
and some studies reported worsened hypertrophy (12–15).
Similar negative results were obtainedwith cardiomyocyte-
restricted expression of dominant-negative p38b (13).
Thus, there is clear discord between pharmacologic and
cardiomyocyte-specific targeted genetic approaches in
ascribing roles to p38a and p38b in cardiac hypertrophy.
A possible unifying explanation for these disparate in
vivo data relates to cell type specificity. Although phar-
macologic inhibitors and global KO models affect all cell
types, cardiac-specific a-myosin heavy chain (a-MHC)-
driven genetic models (KO or dominant negative) specif-
ically target cardiomyocytes. It has been widely assumed
that the inhibitory effects of p38 inhibitors on cardiac hy-
pertrophy are due to direct inhibition of p38 activity in
cardiomyocytes,with little attention given to other cardiac
cell types.
Cardiac fibroblasts are one of the most-prevalent,
nonmyocyte cell populations in the heart, accounting
for between one-fifth and two-thirds of cardiac cells,
depending on the species (16–18). Although traditionally
viewed solely in relation to extracellular matrix remodel-
ing, cardiac fibroblasts are now acknowledged as being
important nodal regulators of multiple aspects of car-
diac function under both physiologic and pathophysio-
logic conditions (19–21). Importantly, recent studies have
revealed that fibroblasts have a critical role in inducing car-
diomyocytehypertrophy in vivo throughparacrine secretion
of growth factors and other signaling molecules (22, 23).
We have previously shown (24) that p38a is the major
subtype expressed by human cardiac fibroblasts, and that
it is important for secretion of several bioactivemolecules,
including matrix metalloproteinase-3 and IL-6 (24–26).
Cardiac-fibroblastp38ahas recentlybeen reported tohave
an important role in myocardial fibrosis after ischemic
injury or chronic neurohumoral stimulation by driving
myofibroblast differentiation and profibrotic signaling
(27). In addition, fibroblast-specific KO of p38a reduced
cardiac hypertrophy (ventricular to body weight ratio)
induced by chronic neurohumoral stimulation (27). It has
been postulated that fibroblast p38a may, therefore, be
important for regulating fibroblast-to-myocyte crosstalk,
resulting in cardiomyocyte hypertrophy (28).
To address the specific role of fibroblast p38a in mod-
ulating cardiac hypertrophy in vivo, we developed an in-
ducible, fibroblast-targeted p38a KO mouse model and
investigated cardiac function and cellular and molecular
changes in a model of cardiac hypertrophy induced by
chronic b-adrenergic stimulation. Our data provide
evidence that cardiac fibroblast p38a is integral to ISO-
induced cardiac hypertrophy and dysfunction and that
this may be due to a paracrine signaling mechanism
involving fibroblast secretion of the cardiomyocyte
hypertrophy-inducing factor, IL-6.
MATERIALS AND METHODS
Animal welfare
All animal procedures were performed in accordance with the
Animal Scientific Procedures Act of 1986 under UKHomeOffice
authorization after review by the University of Leeds Animal
Welfare and Ethical Review Committee. Mice were maintained
in individually ventilated cages at 21°C, 50–70% humidity, 12-h
light/dark cycle with Pure-o’Cel paper bedding (Datesand
Group, Manchester, United Kingdom) and ad libitum access to
water and RM1 Diet (Special Diets Services, Witham, United
Kingdom).
Generation of KO mouse models
Atamoxifen-inducible fibroblast-specific p38aKO (Fb-p38aKO)
mouse linewasestablishedbycrossingC57BL/6miceexpressing
fibroblast-specific, tamoxifen-inducible Cre recombinase
[Col1a2-Cre-ER(T)] (29, 30), with C57BL/6 mice expressing a
modified p38a (Mapk14) gene with exons 2–3 flanked by loxP
sites (31) (Fig. 1A and Supplemental Fig. 1). The Col1a2-Cre-
ER(T) linewas obtained fromChrisDenton (UniversityCollege
London) (29, 30), and theMapk14fl/fl mice were obtained from
Juan-Jose Ventura (University of Cambridge, Cambridge,
United Kingdom). The Col1a2-Cre-ER(T) line induces gene
deletion in cardiac (and other) fibroblasts without effects on
cardiomyocytes, endothelial cells, smooth muscle cells, pro-
genitor cells, pericytes. or macrophages (32, 33). Fb-p38a KO
mice (i.e., Cre-positive Mapk14fl/fl) were compared alongside
control littermates (i.e., Cre-negative Mapk14fl/fl) for the main
experimental protocols. Mice were injected with tamoxifen
dissolved in corn oil (100mg/kg/d, i.p. for a consecutive 5 d) at
3 wk old to induce Cre activity and facilitate loxP-directed
deletion.
The global IL-1 receptor (Il1r1) KOmouse line was generated
by crossing PGK-Cre global deleter mice (The Jackson Labora-
tory, BarHarbor,ME,USA)with floxed Il1r1mice (34) (provided
by E. Pinteaux, University of Manchester, Manchester, United
Kingdom).
Genotyping PCR
DNA was extracted from ear notch samples with the phenol:
chloroform extraction method after incubation of samples over-
night at 37°C in lysis buffer [50mMEDTA, 10mMTris-HCl (pH
8.0), 1% (w/v) SDS, 0.5 mg/ml proteinase K]. End-point PCR
(94°C for 3min; 35 cycles of 94°C for 30 s, 62°C for 30 s, and 72°C
for 30 s; 72°C 3 for min, and a 4°C hold) was performed with
specific primer pairs: Cre forward 59-GCATTACCGGTC-
GATGCAACGAGTGATGAG-39; Cre reverse 59-GAGTGAAC-
GAACCTGGTCGAAATCAGTGCG-39; p38fl forward (X)
59-CTACAGAATGCACCTCGGATG-39; p38fl reverse (Y)
59-AGAAGGCTGGATTTGCACAAG-39; and p38 deletion
forward (Z); 59-CCAGCACTTGGAAGGCTATTC-39; p38
deletion reverse (Y) 59-AGAAGGCTGGATTTGCACAAG-39.
Agarose gel electrophoresis was used to identify the presence
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of Cre (408 bp), floxed Mapk14 (188 bp floxed, 121 bp wild
type), and the deletion of Mapk14 exons 2-3 (411 bp).
Cardiac fibroblast culture
Cardiac fibroblasts were cultured from mouse hearts by colla-
genase digestion, as previously described (35). Briefly, hearts
were thoroughly washed in PBS and minced before digestion
with type II collagenase (2 mg/ml, 600 IU/ml; Worthington
Biochemical, Lakewood, NJ, USA) at 37°C for 90 min with reg-
ular shaking. Cells were pelleted by centrifugation and washed
twice in culture medium before seeding into 3 wells of a 6-well
tissue culture plate (one each for DNA, RNA, and protein
analysis) or a 25-cm2 cell culture flask for subsequent passaging.
Nonadherent cells were removed after 30 min, and cells in-
cubated with full growth medium (DMEM + 10% fetal calf se-
rum). Cells were washed twice with PBS the next day to remove
residual nonadherent cells, and fresh growth medium was
added. Primary cultures of cells were analyzed for p38a ex-
pression 4 d after plating. Passage 1 cells were used for in vitro
mechanistic studies.
Cardiac cell fractionation
Collagenase-digested hearts were filtered through a 30-mmmag-
netic antibody cell separation (MACS) SmartStrainer (Miltenyi
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Figure 1. Inducible ﬁbroblast-speciﬁc deletion of p38a in mouse heart. A) Schematic diagram of the deletion strategy, combining
Col1a2-Cre-ER(T) mice with ﬂoxed Mapk14 mice. Deletion of exons 2–3 occurs after tamoxifen injection, which activates Cre-
ER(T). Red arrowheads denote position of genotyping primers X, Y, and Z (see Materials and Methods). B) Genotyping PCR
showing effective exon 2/3 deletion in ear notch samples from tamoxifen-injected, experimental Cre-positive Mapk14ﬂ/ﬂ mice
(E1–2) compared with control Cre-negative Mapk14ﬂ/ﬂ mice (C1–3). Top: Cre primers (Cre = 408 bp). Bottom: Mapk14 exon
2/3 ﬂoxed/deletion primers. Deletion (Z + Y) = 411 bp; ﬂoxed (X + Y) = 188 bp; and M = 100-bp ladder. C) Real-time RT-PCR
analysis of Mapk14 mRNA levels in primary cultures of cardiac ﬁbroblasts from control (Ctrl) Cre-negative Mapk14ﬂ/ﬂ mice (n = 6)
and Cre-positive Mapk14ﬂ/ﬂ KO mice (n = 8) after tamoxifen injection. *P , 0.05. D) Immunoblot analysis of p38a protein in
primary cultures of cardiac ﬁbroblasts from control Cre-positive Mapk14wt/wt (C), heterozygous Cre-positive Mapk14wt/ﬂ (Het), and
experimental Cre-positive Mapk14ﬂ/ﬂ mice (E1–4) after tamoxifen injection. b-actin loading control. E) Densitometric analysis of
p38a protein expression relative to b-actin in control, heterozygous (Het), and experimental (KO) cells. *P , 0.05. F)
Characterization of nonmyocyte, isolated cell fractions from collagenase-digested mouse hearts (n = 7). Fr1, endothelial cells and
leukocytes; Fr2, cardiac ﬁbroblasts. Bar charts show quantitative RT-PCR data for mRNA levels of cell type–speciﬁc marker genes.
Cardiomyocyte marker, Myh6; endothelial marker, Pecam1; ﬁbroblast markers, Ddr2, Pdgfra, Col1a1, and Col1a2. All data normalized
to Gapdh mRNA levels and expressed relative to whole heart. **P , 0.01, ***P , 0.001. G) Real-time RT-PCR analysis of Mapk14
mRNA levels in isolated cell fractions from hearts of control Cre-negative Mapk14ﬂ/ﬂ mice (n = 3) and experimental Cre-positive
Mapk14ﬂ/ﬂ KO mice (n = 4) after tamoxifen injection. NS, not signiﬁcant. **P , 0.01.
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Biotec, Bergisch Gladbach, Germany) to remove cardiomyocytes.
Nonmyocytes were separated into 2 fractions: nonfibroblasts
(endothelial cells and leukocytes) and fibroblasts with a Cardiac
Fibroblast MACS Separation Kit (Miltenyi Biotec). RNA was
extracted fromcell fractions, andquantitativeRT-PCRwasused to
quantify mRNA for cell type–specific marker genes andMapk14.
Gene expression levels were compared with those obtained from
collagenase-digested whole heart.
RNA extraction, cDNA synthesis, and
real-time RT-PCR
RNA was extracted from cultured/fractionated cells with
the Aurum RNA Extraction Kit (Bio-Rad Laboratories, Her-
cules, CA, USA) or from heart tissue by Tri Reagent (Milli-
poreSigma, Burlington, MA, USA). cDNA was synthesized
with a reverse-transcription system (Promega, Madison, WI,
USA). Real-time RT-PCR was performed with an ABI-7500
SystemwithGene ExpressionMasterMix and specific Taqman
primer/probe sets (Thermo Fisher Scientific, Waltham,
MA, USA): Ace (Mm00802048_m1), Agt (Mm00599662_m1),
Col1a1 (Mm00801666_g1), Col1a2 (Mm00483888_m1),
Col3a1 (Mm01254476_m1), Ddr2 (Mm00445615_m1), Fgf2
(Mm01285715_m1), Igf1 (Mm00439560_m1), Il6 (Mm00446190_
m1), Mapk14 (Mm00442498_m1), Myh6 (Mm00440354_m1),
Myh7 (Mm00600555_m1), Nppa (Mm01255747_g1), Pdgrfa
(Mm00440701_m1), Pecam1 (Mm01242584_m1), Ren1
(Mm02342887_mH), and Tgfb1 (Mm01178820_m1). Data
are expressed relative to the Gapdh housekeeping gene mRNA
expression (Mm99999915_g1 primer/probes) with the cycle
threshold (22DCt) method.
Western blotting
Western blotting was performed on cell homogenates, as pre-
viously described (36, 37) using Cell Signaling Technology (New
EnglandBioLabs, Ipswich,MA,USA) antibodies for p38a (9228),
phospho-p38 (9211), and phospho-HSP27 (2401). Horseradish
peroxidase–conjugated anti-mouse and anti-rabbit secondary
antibodies and enhanced chemiluminescence detection reagent
were from GE Healthcare Life Sciences (Little Chalfont St. Giles,
United Kingdom). mAb b-actin (ab8226) from Abcam (Cam-
bridge, United Kingdom)was used as a loading control. The p38
inhibitor SB203580 (Merck, Kenilworth, NJ, USA) was used to
evaluate the importance of p38a in mediating DAMP-induced
changes in hypertrophic gene expression.
Isoproterenol infusion
Alzet 1002 mini-osmotic pumps (Alzet, Cupertino, CA, USA)
were implanted s.c. in isoflurane-anesthetized mice (control and
Fb-p38a KO) as previously described by Ainscough et al. (37),
and saline or ISO (30 mg/kg/d) was infused for 14 d. Pumps
were removed under isoflurane anesthesia before recovery, and
analysis of cardiac function occurred 1 wk later. Group sizes
were the following: control-saline (n = 11), control-ISO (n = 9),
Fb-p38a KO-saline (n = 8), and Fb-p38a KO-ISO (n = 11).
Measurement of cardiac function and cardiac
weight index
Physiologicalmeasurements of cardiac functionwereobtainedat
the end of the experimental period by Millar conductance
pressure–volume (PV) catheter analysis as previously described
by Frentzou et al. (38). Briefly, mice were anesthetized with iso-
flurane, and body temperature was maintained with a heating
pad before inserting a 1.4 F miniature PV catheter (PVR-1045/
SPR-839Millar;AdInstruments, BellaVista,NSW,Australia) into
the left ventricle via the right carotid artery and ascending aorta.
Data were collected via an MPVS-300 PV system (Millar; ADIn-
struments), and PV loop analysis was performed with Chart 8
Pro software (AdInstruments). Seven animals (18%) did not
survive thePVprocedure, resulting in finalgroupsizesof control-
saline (n = 9), control-ISO (n = 8), Fb-p38a KO-saline (n = 7), and
Fb-p38a KO-ISO (n = 8). The investigator performing the PV
measurements was blinded to the genotype of the animals.
Hearts were subsequently excised, cleaned, atria removed,
and ventricleswereweighed. Tibiaewere collected, cleaned, and
measured. Cardiac weight index was calculated as the ratio of
ventricular weight to tibia length. Ventricles were snap frozen
and were stored at280°C for further analysis.
Histology
Cryosections of ventricular tissue (8 mm thickness) were moun-
ted on poly-L-lysine–coated slides and fixed with 4% para-
formaldehyde for 20 min. Sections were incubated with
rhodamine-labeled wheat germ agglutinin (WGA, 1:1000; Vec-
tor Laboratories, Burlingame, CA, USA) for 2 h, washed with
PBS, then mounted with VectaShield containing DAPI (Vector
Laboratories). Confocal images were captured with a Zeiss Axio
Observer Z1m SP microscope (LSM700) with340 objective and
Zeiss Zen 2.1 SP1 software (Carl Zeiss, Oberkochen, Germany).
Histological measurements were performed in a blinded
fashion by 2 independent observers. Cardiomyocyte cross-
sectional areas (37), and areas of interstitial fibrosis (37, 39)
were quantified using Fiji–ImageJ software (National Institutes
of Health, Bethesda, MD, USA), with at least 10 fields of view
analyzed per animal, and 7–8 animals studied per group.
MicroRNA RT-PCR array
cDNAwas synthesized from 4 cardiac RNA samples for each of
3 groups (control-saline, control-ISO, and Fb-p38aKO-ISO)with
the miScript II Reverse Transcription Kit (Qiagen, Hilden, Ger-
many) before performing a miScript microRNA (miRNA) PCR
array (MIMM-113ZA; Qiagen) with the ABI-7500 real-time PCR
system. This SYBR-green–based array enabled expression levels
of 84 cardiovascular-related miRNAs to be analyzed. Data are
expressed relative to the geometric mean of the 6 normalization
controls includedon thearray (SNORD61,SNORD68,SNORD72,
SNORD95, SNORD96A, and RNU6-2) by the 22DCtmethod.
Preparation of cardiac damage-associated
molecular patterns
Murine hearts were excised, cleaned, and subjected to freeze/
thaw and homogenization in 2ml PBS per heart to disrupt tissue
andcellular structure.The resultanthomogenatewas centrifuged
to remove debris, and the supernatantwas filter-sterilized before
portioning into aliquots for long-term storage at 280°C. Those
cardiac damage-associated molecular pattern (DAMP) prepara-
tions were used at a 1:10 dilution for cell culture studies. Several
separate DAMP preparations were used throughout the study;
all of which gave similar results.
Statistical analysis
Statistical analyses were performed with Prism 6 software
(GraphPad Software, La Jolla, CA, USA). All data are expressed
as means 6 SEM, where n represents the number of separate
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animals investigated or the number of separate hearts from
which cells were isolated. Data were analyzed by Student’s t test
or 1-way ANOVAwith the Sĭda´k post hoc test, as appropriate. A
value of P, 0.05 was considered statistically significant.
RESULTS
Generation of mice with inducible,
fibroblast-specific deletion of p38a
To investigate the role of cardiac fibroblast p38a in hy-
pertrophic cardiac remodeling,wegeneratedan inducible,
fibroblast-specific p38a KO mouse line, which involved
crossing mice expressing fibroblast-specific, tamoxifen-
inducible Cre recombinase [Col1a2-Cre-ER(T)] (29, 30)
withmice expressing amodified p38a gene,Mapk14, with
exons 2–3 (coding for the ATP-binding site of the kinase
domain) flanked by loxP sites (31) (Fig. 1A and Supple-
mental Fig. 1). Tamoxifen injection of mice at 3 wk old
induced Cre activity and the resultant Cre-lox–directed
deletion of Mapk14 exons 2–3 (Fig. 1A). Deletion was
confirmed initially by PCR genotyping of ear notches (i.e.,
dermal fibroblasts) (Fig. 1B) and confirmed in cell cultures.
Primary cultures of cardiac fibroblasts from hearts of Fb-
p38aKOmicehada50%reductionofMapk14mRNA(Fig.
1C) andp38aprotein (Fig. 1D,E) comparedwith cells from
control mice. Knockdown in freshly isolated cardiac cells
was investigated by digesting hearts with collagenase
before separating nonmyocytes into 2 distinct cell types
with a MACS technique. Endothelial cells (Pecam1+ cells)
were separated into fraction 1, along with leukocytes,
whereas fibroblasts (Ddr2, Pdgfra, Col1a1, and Col1a2+)
were separated into fraction 2 (Fig. 1F). Evaluation of rel-
ativeGapdhmRNA expression in the 2 fractions indicated
that;64% of nonmyocytes were present in fraction 1 and
32% in fraction 2, in agreementwith recent comprehensive
studies byPinto et al. (18) on the cellular compositionof the
murine heart. A 65% reduction in Mapk14 mRNA levels
was observed in the fibroblast-enriched fraction 2 from
Fb-p38a KO mice compared with control mice (Fig. 1G).
No reduction inMapk14mRNA levels was evident in the
endothelial cell/leukocyte-enriched fraction 1 (Fig. 1G),
confirming the fibroblast-specific nature of the deletion.
The extent of p38a depletion that we observed in isolated
fibroblasts (65%) was similar to that reported by Lal et al.
(32) in previous studies with the Col1a2-Cre-ER(T)
approach.
Fibroblast-specific p38a KO protects against
catecholamine-induced cardiac hypertrophy
in vivo
The effect of fibroblast-specific p38a KOwas investigated
in a model of cardiac hypertrophy induced by chronic
b-adrenergic stimulation. Control or Fb-p38a KO mice
were injected with tamoxifen at 3 wk old, and then, at
10–12 wk old, they were implanted with osmotic mini-
pumpsdeliveringsalineor ISO(30mg/kg/d) for14d (Fig.
2A). Pumpswere removed, and the animalswere left for 1
additional week before analyzing cardiac function by PV
catheter recordings (Fig. 2B). In controlmice, characteristic
ISO-induced cardiac dysfunction and dilatation were ob-
served, as measured by several hemodynamic indices,
including reduced ejection fraction (EF; control = 70.6 6
4.0, ISO= 43.76 3.6%; P, 0.001), reduced stroke volume
(control = 18.0 6 1.0, ISO = 13.0 6 1.8 ml; P , 0.05),
reduced cardiac output (control = 10,509 6 744, ISO =
7476 6 1028 ml/min; P = 0.06), and increased end sys-
tolic volume (ESV; control = 8.96 1.3, ISO = 17.76 1.8ml;
P , 0.001) (Fig. 2C). Fb-p38a KO mice exhibited re-
markable protection against ISO-induced cardiac dys-
function. In Fb-p38a KO mice, ISO treatment did not
significantly affect EF (ISO= 63.96 4.8%), stroke volume
(ISO = 17.6 6 1.4 ml), cardiac output (ISO = 10,940 6
1018 ml/min), or ESV (ISO = 11.2 6 2.0 ml) (Fig. 2C).
Cardiac hypertrophy was investigated by measuring
cardiac weight index (ventricular weight/tibia length
ratio), expression of hypertrophy-associated fetal car-
diomyocyte genes and cardiomyocyte cross-sectional area
(Fig. 3). In control mice, ISO induced significant increases
of 9% in cardiac weight index (Fig. 3A), 4.6-fold in atrial
natriuretic factor (Nppa) mRNA expression, 8.6-fold in
b-MHC (Myh7) mRNA expression (Fig. 3B) and 43% in
cardiomyocyte cross-sectional area (Fig. 3C,D). Strikingly,
Fb-p38a KO mice showed very little evidence of ISO-
induced cardiac hypertrophy measured by any of these
methods (Fig. 3A–D). ISO infusion also promoted signifi-
cant interstitial fibrosis in control mice, but not in Fb-p38a
KO mice, as evidenced by WGA staining (Fig. 3E, F). No
differences were evident in collagen mRNA expression
(Col1a1 or Col3a1) at the end of the experiment (Fig. 3B),
suggesting much of the active remodeling had been re-
solved by this 3-wk point.
A focused miRNA array was employed to investigate
the effect of ISO on selected cardiovascular miRNAs and
the influence of fibroblast-specific p38a KO (Fig. 4 and
Table 1). RNA samples prepared from hearts of saline-
infused control mice were compared with those of ISO-
infused control mice and ISO-infused Fb-p38a KO mice
(4 hearts/group), and expression levels of 84 cardiovas-
cular miRNAswere evaluated (see Supplemental Table 1
for full data set). The 10 most highly expressed miRNAs
in control hearts from saline-infused animals included
miR-1a, miR-126a, miR-24, and multiple members of
the miR-23, miR-26 and miR-30 families (Table 1). Of
the 84 miRNAs studied, 12 were reproducibly increased
in hypertrophic hearts from ISO-infused mice compared
with hearts from saline-infused mice (miR-21a, -24,
-27a/b, -29a/c, -140, -199a, -208a/b, -214, and -224), and 2
miRNAs were decreased in ISO hearts compared with
saline hearts (miR-30d and -150) (Fig. 4A). Fibroblast-
specific p38a KO opposed the effects of ISO on some of
those miRNAs, namely, miR-208b, -21a, -214, -224, and
-30d (Fig. 4B). P38aKOalso inducedmiR-328 expression,
although it was not modulated by ISO, suggesting nega-
tive regulation of thatmiRNAby fibroblast p38a (Fig. 4B).
Taken together, these in vivo data demonstrate that
fibroblast-specific p38a KO confers cardioprotective ben-
efits by attenuating ISO-induced cardiac hypertrophy and
dysfunction. Given that cardiac fibroblasts have a critical
role in stimulating cardiomyocyte hypertrophy through
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paracrine secretion of hypertrophic growth factors, we
hypothesized that cardiac fibroblast p38a was important
for secretion of such factors and could, thereby, stimulate
cardiomyocyte hypertrophy.
Cardiac fibroblast p38a is required for
damage-induced secretion of the
cardiomyocyte hypertrophy-inducing
factor IL-6
We first investigated whether ISO could directly activate
p38 MAPK in cultured cardiac fibroblasts, and then,
whether it could induce specific myocyte hypertrophy-
inducing factors (FGF-2, IGF-1, TGF-b1, and IL-6) in a
p38a-dependentmanner. Although ISOdirectly activated
fibroblast p38a (Fig. 5A), it was unable to stimulate ex-
pression of any of the hypertrophy-inducing genes tested
(Fig. 5B).
Wenext investigatedwhether ISOcouldbemodulating
fibroblast function indirectly by inducing cardiac damage,
resulting in release of DAMPs and fibroblast activation
(20). To mimic that in vitro, we prepared cardiac DAMPs
by freeze-thawing and homogenizing mouse heart tissue.
That cardiac DAMP preparation activated p38a when
added to cultured cardiac fibroblasts (Fig. 5A). Cardiac
DAMPs did not modulate Fgf2mRNA levels but strongly
stimulated Il6 mRNA expression by .10-fold and in-
creased Tgfb1mRNA levels by 50% after 6 h (Fig. 5B). The
DAMP preparation had the opposite effect on Igf1mRNA
levels, decreasing them by 50% (Fig. 5B).
The cardiac DAMP preparation represented a hetero-
geneous mixture of cellular proteins, nucleic acids, and
biochemicals, mimicking the DAMPs released after car-
diac damage that induces an innate immune response (20,
40). We investigated which specific components of the
cardiac DAMP preparation were responsible for acti-
vating p38a and IL-6 expression in cardiac fibroblasts
(Supplemental Fig. 2). Those experiments involved 1)
testing its efficacy in cardiac fibroblasts that lacked the
IL-1 receptor IL-1R1because IL1ahas been shown to be a
potential DAMP in this setting (41), and 2) investigating
whether inhibition of the TLR4 would inhibit the effects
of DAMPs because that pattern recognition receptor has
been shown to mediate the effects of several DAMPs on
cardiac fibroblasts (20). Our studies revealed that the
effects of the cardiac DAMP preparation on cardiac fi-
broblasts occurred independent of IL-1R1 or TLR4
(Supplemental Fig. 2).
Further investigation into the timing of the effects of
cardiac DAMPs on gene expression revealed that the
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increase in Il6 and Tgfb1 mRNA expression returned to
basal levels within 24 h, whereas the reduction in Igf1
levels wasmaintained for at least 48 h (Fig. 6A). Despite
the relatively transient nature of Il6mRNA expression,
ELISA analysis of the conditionedmedium confirmed a
sizeable elevation in IL-6 protein secretion in response
to cardiac DAMPs, with peak levels of .10 ng/ml
maintained for 24–48 h after the initial stimulus (Fig.
6B). The p38 inhibitor SB203580 was used to evaluate
the importance of p38a in mediating DAMP-induced
changes in hypertrophic gene expression. SB203580
prevented p38a downstream signaling, as expected (Fig.
6E), and significantly reduced DAMP-induced Il6 mRNA
expression and protein secretion (Fig. 6C,D). In contrast, the
p38 inhibitor had no effect onDAMP-induced expression of
Tgfb1 or Igf1 mRNA (Fig. 6C). Together these data indicate
that cardiac DAMPs can stimulate IL-6 transcription and
protein secretion inap38a-dependentmanner; amechanism
that may underlie our in vivo observations on cardiac
hypertrophy.
To evaluate whether IL-6 was up-regulated by chronic
ISO infusion in vivo and modulated by fibroblast-specific
p38a KO, we measured Il6 mRNA levels in whole-heart
samples at the end of the experimental protocol. Those
data (Fig. 6F) revealed a trend toward increased Il6mRNA
expression in hearts from ISO-infused control mice,
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compared with those with saline infusion, and a trend
toward decreased Il6 mRNA in hearts from ISO-infused,
fibroblast-specific p38a KO mice compared with ISO-
infused control mice.
To determine whether fibroblast p38a was important
for expression of the renin–angiotensin system (RAS)
genes in fibroblasts and, thereby, potentially contributing
to our in vivo findings by inhibiting local RAS activation,
we investigated the effect of the p38 inhibitor SB203580 on
RASgene expression in culturedmouse cardiac fibroblasts
(Supplemental Fig. 3A).Neither angiotensinogen (Agt) nor
angiotensin-converting enzyme (Ace) mRNA levels were
affected by 6 h of exposure to SB203580, conditions that
reduced Il6 mRNA levels by .50%. Moreover, the
cardiac DAMP preparation had the opposite effect on
Agt and Ace expression, compared with Il6 expression,
reducing their mRNA levels by 40–50% (Supplemental
Fig. 3B). Renin (Ren1) mRNAwas not detectable in any
of these samples.
DISCUSSION
Our study demonstrated that fibroblast-specific KO of
p38anegates thedeleterious effects of chronicb-adrenergic
receptor stimulation on cardiac hypertrophy and function.
Specifically, our in vivo experiments revealed that fibroblast-
specific p38a KO prevented the ability of chronic ISO in-
fusion to reduce EF, increase ESV, increase the ratio of
ventricular weight/tibia length, increase cardiomyocyte
area, increase fibrosis, up-regulate myocyte hypertrophy
markers (atrial natriuretic factor, b-MHC), up-regulate pro-
hypertrophicmiRNAs, anddown-regulate antihypertrophic
miRNAs. Our supporting in vitro experiments indicated a
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key role for p38a in mediating DAMP-induced secretion of
the cardiomyocyte hypertrophy-inducing factor IL-6 from
cardiac fibroblasts. Our study, therefore, suggests that
cardiac fibroblast p38a is important for regulating car-
diomyocyte hypertrophy throughparacrine fibroblast-to-
myocyte signaling involving IL-6 secretion (Fig. 6G).
Despite nearly 2 decades of study, the precise, indi-
vidual roles of p38a and p38b in modulating car-
diomyocyte hypertrophy remain unclear,with seemingly
contradictory outcomes reported (2, 3, 10). Results from
in vitro, ectopic, overexpression studies of individual
p38 subtypes in cardiomyocytes are at odds with
cardiomyocyte-targeted in vivo genetic inhibition stud-
ies, yet pharmacologicp38a inhibitionappears effective at
reducing cardiac hypertrophy. Our data offer a potential
unifying explanation by uncovering a role for cardiac fi-
broblast p38a inmodulating cardiomyocyte hypertrophy
in vivo.
Many stimuli that cause LV hypertrophy (e.g., cat-
echolamines, Ang II, and pressure overload) are direct
inducers of cardiomyocyte cellular hypertrophy in vitro,
and that has been assumed to underlie their hypertrophic
action on the heart. However, that concept has been
challenged by several recent studies showing that fibro-
blasts act as primary integrators of hypertrophic stimuli in
the intact heart (22, 23). A number of paracrine-signaling
molecules have been identified through which fibroblasts
can modulate cardiomyocyte hypertrophy, including
FGF2, IGF-1, and TGF-b. Additionally, we hypothesized
that IL-6 may act in this manner because that cytokine is
up-regulated inmouse hearts after 1–2wk of ISO infusion
(42, 43), is actively secreted from cardiac fibroblasts in re-
sponse tob-adrenergic receptor stimulation orAng II (19),
and is able to directly induce cardiomyocyte hypertrophy
(44, 45), and IL-6 KO mice are protected against LV hy-
pertrophy in response to noradrenaline, Ang II, or pres-
sure overload (44, 46, 47). Moreover, cardiomyocyte
hypertrophy induced in vitro by either Ang II or phenyl-
ephrine is impaired in myocytes isolated from IL-6 KO
mice (44), suggesting that autocrine IL-6 secretion is nec-
essary for induction of myocyte hypertrophy by those
stimuli. A diverse range of stimuli have been reported to
induce IL-6 expression in cardiac fibroblasts in a p38-
dependent manner, including IL-1, IL-33, TNF-a, Ang II,
adenosine, and a/b-adrenergic receptor agonists (1, 48,
49). Thus, the p38pathwayappears to have a fundamental
role in stimulating IL-6 secretion from cardiac fibroblasts
in response to a variety of molecules up-regulated during
cardiac injury and remodeling. In agreement with our
hypothesis, a key paracrine role for fibroblast-derived
IL-6 has recently been found to account for the cardiac
hypertrophy observed in a mouse overexpressing
fibroblast/smooth-muscle cell–targeted sphingosine 1
phosphate receptor-1 (50). Those previous studies, to-
getherwith our current in vitromechanistic data, suggest
a scenario whereby cardiac fibroblast p38a stimulates
cardiomyocyte hypertrophy by sensing damage to the
heart and inducing IL-6 paracrine crosstalk (Fig. 6G).
However, the role of fibroblast p38a in regulating car-
diomyocyte hypertrophy is likely to be more complex
than simply altering the secretion of a single paracrine
hypertrophic factor. Further studies will, therefore, be
required to unequivocally define the importance of car-
diac fibroblast-derived IL-6 in this setting.
The miRNA microarray identified several highly
expressed miRNAs in the murine heart tissue of controls,
with miR-1, -126a, and -30c being the most abundant. Of
the 84 miRNAs studied, 12 were reproducibly increased,
and 2 were decreased in hypertrophic hearts from ISO-
infused mice compared with hearts from saline-infused
mice. Many of these miRNAs have been shown to be
modulated similarly in other reports on mouse and rat
models of cardiac hypertrophy (51–55). We identified
5 miRNAs that were significantly regulated by ISO in
control mice but not in Fb-p38a KO mice (miR-21a, -214,
-224, -208b, and -30d), suggesting they are important for
the cardioprotective effect of fibroblast-specific p38a KO.
Both miR-21 and miR-214 are highly expressed by car-
diac fibroblasts and have important roles in myocardial
remodeling (56–59). Notably, both those miRNAs posi-
tively regulate IL-6 expression in macrophages and
fibroblast-like ligamentum flavum cells (60, 61) and may,
therefore, have similar roles in cardiac fibroblasts, con-
tributing to the paracrine IL-6 hypertrophic effect we
describe. Recent studies have shown thatmodulation of
miR-21 in cardiac fibroblasts in vivo positively regulates
paracrine hypertrophic signaling induced by pressure
overload (56). Much less well studied is miR-224 in the
heart, but it is also expressed by cardiac fibroblasts, and
its levels are up-regulated by Ang II (62). Potential
TABLE 1. Expression of miRNAs in control hearts
miRNA Expression (22DCt)
1a 75.4
126a 18.1
30c 11.5
23a 8.2
26a 5.6
26b 5.6
30a 4.7
23b 4.6
24 4.6
30e 4.1
125b 3.9
195a 3.3
451a 3.1
16 2.8
27a 2.7
let-7f 2.7
378a 2.7
21a 2.6
30d 2.5
125a 2.1
29c 2.1
29a 2.0
Control (Cre-negative) mice were injected with tamoxifen and
infused with saline, as described in Fig. 2A. Heart tissue was collected
1 wk after removal of miniosmotic pumps, and expression levels of 84
cardiovascular miRNAs were determined using a real-time RT-PCR
array. Group sizes: n = 4. See Supplemental Table 1 for full data set.
Table lists the 22 most highly expressed miRNAs in control hearts from
saline-infused mice. Data are mean expression levels (22DCt) relative to
array-normalization controls.
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target genes for miR-224 include several that regulate
cardiac fibroblast proliferation and cardiac fibrosis (62).
MiR-208b is cardiomyocyte specific because it is located
within an intron of the b-MHC (Myh7) gene (63); hence,
its increase was expected, given the increase in Myh7
mRNAexpression observed in ISO hearts. Finally,miR-
30d, which we found was reduced in control hyper-
trophic hearts but not fibroblast-specific p38a KO
hearts, has previously been shown to be reduced with
pressure overload–induced cardiac hypertrophy (53).
Interestingly, several other members of the miR-30
family are also known to regulate cardiac hypertrophy
and fibrosis (64, 65). We identified just 1 miRNA (miR-
328) that was elevated in ISO-infused p38 KO hearts,
compared with ISO-infused control hearts, suggesting
negative regulation by fibroblast p38a. Indeed, miR-
328 has been shown to be negatively regulated by p38 in
human osteosarcoma cells (66). Furthermore, miR-328
was recently reported to regulate myocardial fibrosis
via effects on cardiac fibroblast function (67).
A marked elevation of cardiac Il6 mRNA levels has
previously been reported LV samples from ISO-infused
mice after 1–2 wk (42, 43). We observed a trend toward
increased Il6 mRNA levels in hearts from ISO-treated
control mice after 3 wk, which was not apparent in hearts
from ISO-treated fibroblast-specific p38 KO mice. How-
ever, Il6mRNA levels were low and the differences were
not statistically significant, which may be explained by
samples being derived from whole heart [in which fibro-
blasts account for,20% of cells (18)] and at the end of the
experimental protocol (i.e., 1 wk after cessation of ISO
treatment); at which time, the effects of ISO on Il6mRNA
expression were likely to be less pronounced (42).
Although we did not identify the precise bioactive
molecule(s) in the cardiac DAMP preparation responsible
for p38a activation and IL-6 expression in cardiac fibro-
blasts, we did establish that those effects occurred in-
dependent of the IL-1R1 or TLR4 receptors. There are
several other candidatemolecules andreceptors that could
fulfill that role (20, 40), including IL-18 (an IL-1 family
cytokine that acts via a different receptor), which has
recently been shown to be up-regulated in response to
ISO treatment in mice, and its release from damaged
cardiomyocytes triggered inflammation andpathologic
cardiac remodeling (68). We also cannot rule out that
combinations of molecules in the DAMP preparation
were driving IL-6 secretion, rather than a single, specific
molecule, especially given the diversity of molecules
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up-regulated in the remodeled heart that are known to
induce IL-6 secretion from fibroblasts in a p38-dependent
manner (1, 48, 49). Hence, more in-depth analyses, be-
yond the scope of the current study, would be required to
identify the precise molecular components of the cardiac
DAMP preparation that trigger p38a activation and IL-6
production in cardiac fibroblasts.
The relationship between the adrenergic system and
the RAS in the setting of cardiac remodeling is complex,
with several points of interaction (69). Rat cardiac fi-
broblasts are reported to express angiotensinogen, renin,
and angiotensin 1–converting enzyme, thereby contrib-
uting to both a localmyocardial RAS and an intracellular
RAS (70). In contrast to that report, we did not detect
Ren1mRNA in murine cardiac fibroblasts; whether that
is a species-specific difference requires further study.
Under basal conditions, Agt and Ace mRNA were not
regulated by p38a, which agrees with a previous study
in rat cardiac fibroblasts (71). Cardiac DAMPs reduced
both Agt and Ace mRNA expression, contrary to the ef-
fects on Il6 mRNA expression. Together, these data ap-
pear to rule out amechanism inwhich fibroblast-specific
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Figure 6. Role of p38a in DAMPs-modulated expression of hypertrophy-inducing genes in cardiac ﬁbroblasts. A) Real-time RT-
PCR showing time of effect of DAMPs on mRNA expression of Il6, Tgfb1, and Igf1. *P , 0.05, **P , 0.01 (n = 3). B) ELISA
showing time of IL-6 secretion from cardiac ﬁbroblasts stimulated with cardiac DAMPs. Red ﬁlled circles represent DAMP-
stimulated IL-6 secretion, and black-ﬁlled squares represent basal secretion without addition of DAMPs (measured up to 6 h
only). *P , 0.05 compared with time 0 (n = 3). C) Real-time RT-PCR data showing effect of 10 mM SB203580 or DMSO vehicle
control on DAMP-induced expression of hypertrophy-inducing genes after 6 h (n = 9). *P , 0.05, **P , 0.01, ***P , 0.001
(ANOVA with Sˇida´k post hoc test). NS, not signiﬁcant. Data normalized to Gapdh mRNA levels and expressed relative to the
control. D) ELISA showing effect of 10 mM SB203580 or DMSO vehicle control on DAMP-induced IL-6 secretion after 6 h (n = 9).
ANOVA with Sĭda´k post hoc test. *P , 0.05; NS, not signiﬁcant. E) Western blot showing DAMP-induced phosphorylation (p-) of
HSP27 and p38a after 20 min and inhibition by 10 mM SB203580. Total p38a expression was included as the loading control.
Blots are representative of 3 separate experiments. F) Control or Fb-p38a KO mice were injected with tamoxifen, and
miniosmotic pumps were implanted for delivery of saline or ISO as in Fig. 2A. Pumps were removed, and heart tissue was
collected 1 wk later. Bar chart shows real-time RT-PCR analysis of cardiac Il6 mRNA levels (means 6 SEM). Group sizes: control
saline (n = 11), control ISO (n = 9), and KO ISO (n = 11). ANOVA with Sĭda´k post hoc test: not signiﬁcant. G) Schematic depicting
role of ﬁbroblast p38a in modulating cardiomyocyte hypertrophy.
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p38a KO directly reduced myocardial RAS activation in
vivo.
Several reports have emerged recently that support a
critical role for cardiac fibroblast p38a in modulating car-
diac remodeling (27, 72, 73). For example, a nonbiased
transcriptomic approach identified cardiac fibroblast
ATF3 as being cardioprotective in heart-failure models;
and fibroblast p38 was identified as the downstream
molecule responsible for profibrotic and hypertrophic
effects in fibroblast-specific ATF3 KO mice [Col1a2-Cre-
ER(T)model] (73). In a secondstudy, global knockdownof
MK5 (a p38 substrate localized to cardiac fibroblasts but
not to myocytes) was associated with the attenuation of
both hypertrophy and cardiac dysfunction in response to
chronic pressure overload (72). Recently, it was reported
that inducible fibroblast-selective knockdown of p38a (in
Tcf21- and Postn-directed Cre KO mouse models) could
reduce myofibroblast differentiation and fibrosis after is-
chemic injury or chronic neurohumoral stimulation (27).
Although focused on fibrosis, that study also noted that
fibroblast-selective p38a KO mice had reduced cardiac
hypertrophy induced by Ang II and phenylephrine in-
fusion (27). Our study defines a clear hypertrophic role for
cardiac fibroblast p38a and identifies IL-6 as a possible
p38a-induced paracrine factor capable of stimulating
cardiomyocyte hypertrophy in this setting. Thus, strong
evidence is accumulating that p38a in cardiac fibroblasts
acts as a central mediator of cardiac hypertrophy and fi-
brosis in a variety of pathologic scenarios, making it an
attractive target for therapeutic intervention.
In summary, our study reveals an important role for
p38a, specifically in cardiac fibroblasts, in stimulating
cardiac hypertrophy after chronic b-adrenergic stimula-
tion, potentially via an IL-6–dependent mechanism. These
findingshelp to explain thedisparitybetween the effects of
pharmacologic p38 inhibitors and cardiomyocyte-specific
KO/inhibition models for inhibiting cardiac hypertrophy
in vivo. They also further our understanding of the key role
that cardiac fibroblasts have in regulating cardiac hyper-
trophy and remodeling through paracrine signaling, and
our findings identify the cardiac fibroblast p38a/IL-6 axis
as a potential therapeutic target in this setting.
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